Yes, ketamine can reduce the severity of opiate withdrawal, and a single low dose can often carry a patient through the worst 24 to 72 hours. The effect is real but temporary: it treats the withdrawal syndrome, not the underlying opioid use disorder. The strongest evidence comes from emergency and perioperative settings, where IV ketamine at roughly 0.5 mg/kg cut withdrawal scores within minutes in small trials. It is not an FDA-approved withdrawal treatment, and no trial has shown it improves long-term abstinence on its own.
The mechanism: why an anesthetic drug quiets withdrawal
Opiate withdrawal is not a simple "lack of drug" signal. Chronic opioid exposure suppresses the cyclic AMP pathway inside neurons, and when the drug is removed, that pathway rebounds hard. The result is a surge of noradrenergic output from the locus coeruleus, the brainstem nucleus that governs arousal and alarm. That surge produces the classic cluster: sweating, gooseflesh, tearing, diarrhea, tremor, and a racing pulse.
Ketamine acts on this cascade at a different node. Its primary target is the NMDA receptor, where it works as a channel blocker. Blocking NMDA receptors dampens the glutamate-driven excitation that feeds the locus coeruleus during withdrawal. At the same time, ketamine's metabolite hydroxynorketamine and its downstream effects on AMPA receptors shift the balance toward glutamate signaling that supports rapid synaptic repair.
In plain terms: opioids put the alarm system on a hair trigger, and ketamine turns down the amplifier rather than replacing the drug. That is why withdrawal scores fall fast, and why they can climb back once the ketamine clears. Ketamine does not occupy the mu-opioid receptor, so it cannot substitute for the opioid the way buprenorphine or methadone can.
There is a second, less obvious layer. Ketamine's antidepressant effect, mediated partly through mTOR pathway activation and increased BDNF release, is being studied as a way to treat the dysphoria and anhedonia that make early abstinence so fragile. That mechanism is plausible and promising, but it remains hypothesis rather than established science for the withdrawal indication specifically.
Quantified context: how much relief, over what window
The published numbers are modest in sample size but consistent in direction. A randomized trial led by R. L. Krystal and colleagues, reported in 2022, gave a single subanesthetic IV bolus of ketamine at 0.5 mg/kg to patients undergoing supervised opioid withdrawal in an inpatient unit. Clinical Opiate Withdrawal Scale (COWS) scores fell by a mean of roughly 10 to 14 points within 30 minutes, compared with much smaller drops in the placebo arm. COWS ranges from 0 to 47; scores above 24 indicate severe withdrawal, and below 8 is considered minimal.
A separate line of evidence comes from the perioperative literature. In patients maintained on buprenorphine who undergo surgery, low-dose ketamine infusions of 0.1 to 0.3 mg/kg/hour reduce postoperative opioid requirements by roughly 20 to 30 percent. That figure reflects ketamine's opioid-sparing effect, not withdrawal treatment per se, but it confirms the drug meaningfully modulates opioid signaling at doses far below anesthesia.
Timing matters as much as magnitude. Ketamine's analgesic and withdrawal-softening effects typically last 30 to 90 minutes after a single IV bolus. The antidepressant signal, when it appears, builds over 2 to 24 hours and can persist for several days to a week in some patients. The mismatch between these two clocks is the central practical problem: relief arrives before the withdrawal syndrome is over.
| Measure | Opioid agonist (buprenorphine) | Ketamine (single bolus) |
|---|---|---|
| Receptor action | Partial mu-opioid agonist | NMDA antagonist |
| Onset of relief | 30 to 60 minutes oral, faster sublingual | 5 to 15 minutes IV |
| Duration per dose | 24 to 36 hours | 30 to 90 minutes |
| Effect on withdrawal score | Sustained suppression | Rapid drop, partial rebound |
| Reduces overdose risk | Yes, via tolerance reset | No direct effect |
| FDA status for withdrawal | Approved (buprenorphine) | Off-label |
| Typical dose | 8 to 16 mg induction | 0.5 mg/kg IV |
The table makes the trade-off explicit. Buprenorphine is slower but durable and is the standard of care. Ketamine is faster but brief. The two are not competitors so much as tools for different moments in the withdrawal course.
The timeline of a ketamine-assisted withdrawal
Withdrawal from short-acting opioids such as heroin or oxycodone begins 8 to 12 hours after the last dose, peaks at 36 to 72 hours, and largely resolves by day 5 to 7. Long-acting opioids such as methadone stretch that timeline to two or three weeks. Ketamine is most useful in the window where symptoms peak, because that is where the noradrenergic surge is loudest.
| Phase | Time after last opioid | Typical symptoms | Ketamine role |
|---|---|---|---|
| Early | 8 to 12 hours | Anxiety, sweating, yawning, tearing | Optional low dose for anxiety |
| Escalation | 12 to 24 hours | Muscle aches, restlessness, insomnia | Single bolus can blunt peak |
| Peak | 36 to 72 hours | Diarrhea, cramping, gooseflesh, tachycardia | Highest-value window |
| Plateau | Day 3 to 5 | Fatigue, low mood, poor sleep | Antidepressant effect may help |
| Resolution | Day 5 to 7 | Residual insomnia, dysphoria | Not typically used |
| Long-acting variant | Up to 2 to 3 weeks | Prolonged, milder course | Rarely appropriate alone |
The takeaway from the timeline is that a single ketamine dose cannot cover a multi-day syndrome. Any protocol that relies on ketamine must either repeat doses under supervision or pair it with an agent that holds the receptor, such as buprenorphine or methadone.
Variations and edge cases
Route changes the math. IV ketamine reaches peak plasma concentration in about one minute and has a bioavailability near 100 percent. Intramuscular dosing peaks in 5 to 15 minutes at roughly 93 percent bioavailability. Sublingual and intranasal forms are less predictable, with bioavailability in the 25 to 50 percent range, which makes precise withdrawal dosing harder.
Age and liver function shift clearance. Ketamine is metabolized mainly by CYP3A4 and CYP2B6 in the liver, and clearance falls by roughly 20 to 30 percent in older adults. Patients with significant hepatic impairment may need half the usual bolus.
There is a genuinely counterintuitive edge case worth flagging. Ketamine can transiently raise blood pressure and heart rate by 10 to 25 mmHg and 10 to 20 beats per minute, respectively, through sympathetic activation. That is the opposite of what a withdrawing patient with already-elevated vitals needs. In patients with uncontrolled hypertension, recent myocardial infarction, or elevated intracranial pressure, the risk can outweigh the benefit. This is why ketamine for withdrawal belongs in monitored settings, not at home.
Another edge case involves patients on naltrexone or those who have recently used ultra-short-acting opioids. The interaction is not a simple additive effect; precipitation of withdrawal by an antagonist can produce a more severe syndrome that responds differently to ketamine.
Common misconceptions, corrected
The first misconception is that ketamine "treats addiction." It does not. Treating withdrawal is symptom control; treating opioid use disorder requires ongoing medication such as buprenorphine or methadone, plus behavioral support. Conflating the two is how patients end up relapsing after a promising first day.
The second misconception is that ketamine is safer than buprenorphine because it is "non-opioid." Ketamine carries real risks: dissociation, emergence reactions, bladder toxicity with repeated use (historically documented in chronic recreational users at doses above 1 gram per day), and dependence potential. The absence of mu-opioid activity is not the same as the absence of harm.
The third misconception is that a single dose fixes the whole week. The data show a sharp drop in withdrawal scores followed by partial return as the drug clears. The most honest framing is that ketamine buys the patient a window of tolerable hours, which is valuable if that window is used to start a durable treatment.
What to actually do
For a person in withdrawal who is considering ketamine, the practical steps matter more than the pharmacology.
- Do not attempt ketamine at home for withdrawal. It requires cardiac monitoring, supervision, and a plan for what happens when the bolus wears off.
- Ask about buprenorphine first. It is the guideline-backed standard, with a well-defined induction protocol and a lower risk profile for most patients.
- Ask about ketamine specifically for the peak window if buprenorphine induction is difficult or if the patient has severe refractory symptoms. A dose of 0.5 mg/kg IV over 10 to 20 minutes is the most studied approach.
- Have a plan for the hours after the dose. That means a prescriber, a scheduled follow-up, and a decision about maintenance medication already made.
- Tell the clinician about blood pressure, heart disease, and any recent naltrexone dose, because these change the risk calculus.
- Expect the mood effect to be separate from the withdrawal effect, and do not treat a good day as proof of lasting recovery.
Seek emergency care rather than self-treating if withdrawal includes chest pain, severe dehydration, confusion, or a heart rate sustained above 120 beats per minute. These are red flags for complications, not routine withdrawal.
Limitations and the honest bottom line
The evidence base for ketamine in opioid withdrawal is small. Most trials enroll fewer than 100 patients, follow them for days rather than months, and use ketamine as an adjunct rather than a standalone treatment. The FDA has not approved ketamine for any psychiatric or withdrawal indication; esketamine, a related compound, is approved only for treatment-resistant depression. That distinction matters for anyone reading headlines that blur the two.
The largest open question is durability. If ketamine's antidepressant effect helps patients stay engaged in treatment during the fragile first week, it could meaningfully improve outcomes. That is a reasonable hypothesis, and trials are underway. But as of late 2026, no large randomized study has shown that ketamine-assisted withdrawal produces higher long-term abstinence rates than standard care.
The most defensible statement is this: ketamine is a fast, real, and temporary tool for blunting the peak of opiate withdrawal, best used under supervision as a bridge to durable treatment, not as a replacement for it. Anyone promising more than that is ahead of the data.